A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Marie L. Landry, Sylvia Stanat, Karen Biron, Donald Brambilla, William Britt, Janet Jokela, Sunwen Chou, W. Lawrence Drew, Alejo Erice, Bruce Gilliam, Nell Lurain, Jody Manischewitz, Richard Miner, Mostafa Nokta, Patricia Reichelderfer, Stephen Spector, Adriana Weinberg, Belinda Yen-Lieberman, Clyde Crumpacker

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

Original languageEnglish (US)
Pages (from-to)688-692
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume44
Issue number3
DOIs
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Cytomegalovirus
Pharmaceutical Preparations
Antiviral Agents
Phenotype
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. / Landry, Marie L.; Stanat, Sylvia; Biron, Karen; Brambilla, Donald; Britt, William; Jokela, Janet; Chou, Sunwen; Drew, W. Lawrence; Erice, Alejo; Gilliam, Bruce; Lurain, Nell; Manischewitz, Jody; Miner, Richard; Nokta, Mostafa; Reichelderfer, Patricia; Spector, Stephen; Weinberg, Adriana; Yen-Lieberman, Belinda; Crumpacker, Clyde.

In: Antimicrobial Agents and Chemotherapy, Vol. 44, No. 3, 03.2000, p. 688-692.

Research output: Contribution to journalArticle

Landry, ML, Stanat, S, Biron, K, Brambilla, D, Britt, W, Jokela, J, Chou, S, Drew, WL, Erice, A, Gilliam, B, Lurain, N, Manischewitz, J, Miner, R, Nokta, M, Reichelderfer, P, Spector, S, Weinberg, A, Yen-Lieberman, B & Crumpacker, C 2000, 'A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates', Antimicrobial Agents and Chemotherapy, vol. 44, no. 3, pp. 688-692. https://doi.org/10.1128/AAC.44.3.688-692.2000
Landry, Marie L. ; Stanat, Sylvia ; Biron, Karen ; Brambilla, Donald ; Britt, William ; Jokela, Janet ; Chou, Sunwen ; Drew, W. Lawrence ; Erice, Alejo ; Gilliam, Bruce ; Lurain, Nell ; Manischewitz, Jody ; Miner, Richard ; Nokta, Mostafa ; Reichelderfer, Patricia ; Spector, Stephen ; Weinberg, Adriana ; Yen-Lieberman, Belinda ; Crumpacker, Clyde. / A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. In: Antimicrobial Agents and Chemotherapy. 2000 ; Vol. 44, No. 3. pp. 688-692.
@article{5590bd0f56374fbbbdea3beb8cff2536,
title = "A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates",
abstract = "Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.",
author = "Landry, {Marie L.} and Sylvia Stanat and Karen Biron and Donald Brambilla and William Britt and Janet Jokela and Sunwen Chou and Drew, {W. Lawrence} and Alejo Erice and Bruce Gilliam and Nell Lurain and Jody Manischewitz and Richard Miner and Mostafa Nokta and Patricia Reichelderfer and Stephen Spector and Adriana Weinberg and Belinda Yen-Lieberman and Clyde Crumpacker",
year = "2000",
month = "3",
doi = "10.1128/AAC.44.3.688-692.2000",
language = "English (US)",
volume = "44",
pages = "688--692",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

AU - Landry, Marie L.

AU - Stanat, Sylvia

AU - Biron, Karen

AU - Brambilla, Donald

AU - Britt, William

AU - Jokela, Janet

AU - Chou, Sunwen

AU - Drew, W. Lawrence

AU - Erice, Alejo

AU - Gilliam, Bruce

AU - Lurain, Nell

AU - Manischewitz, Jody

AU - Miner, Richard

AU - Nokta, Mostafa

AU - Reichelderfer, Patricia

AU - Spector, Stephen

AU - Weinberg, Adriana

AU - Yen-Lieberman, Belinda

AU - Crumpacker, Clyde

PY - 2000/3

Y1 - 2000/3

N2 - Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

AB - Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

UR - http://www.scopus.com/inward/record.url?scp=0033996648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033996648&partnerID=8YFLogxK

U2 - 10.1128/AAC.44.3.688-692.2000

DO - 10.1128/AAC.44.3.688-692.2000

M3 - Article

C2 - 10681339

AN - SCOPUS:0033996648

VL - 44

SP - 688

EP - 692

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -